1/1

2 files

Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019

media

posted on 2021-03-11, 09:33 authored by Adis journals on behalf of, Alanna C. McEneny-King, Jonathan P. R. Monteleone, Shamsah D. Kazani, Stephan R. Ortiz

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.

History

References

https://link.springer.com/article/10.1007/s40121-021-00425-7

Usage metrics

Read the peer-reviewed publication

Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019

Infectious Diseases and Therapy

Infectious Diseases and Therapy

Categories

Keywords

Antibodies Complement C5/*antagonists & inhibitors Complement Inactivating Agents/*therapeutic use Coronavirus disease 2019 Humanized/*therapeutic use Monoclonal Ravulizumab Terminal complement pathway Plain Language Summary

Licence

Exports